Thursday, December 30, 2021 15:47:31 UTC
BIONTECH SE: We entered a call option, $250.00 strike price, at 9:30 AM with a limit buy. We exited 1 hour later by limit sale for a 157% profit!
Taking profits, selling 1/3 position.(More)
RELATED:
Tue, Dec 28, 21
NVAX: Novavax Inc
Thu, Dec 23, 21
NVAX: Novavax Inc
Tue, Dec 21, 21
NVAX: Novavax Inc
Wed, Dec 8, 21
PFE: Pfizer Inc
RELATED:
Tue, Dec 28, 21
NVAX: Novavax Inc
Thu, Dec 23, 21
NVAX: Novavax Inc
Tue, Dec 21, 21
NVAX: Novavax Inc
Wed, Dec 8, 21
PFE: Pfizer Inc
Tuesday, December 21, 2021 20:12:17 UTC
NOVAVAX INC: We entered a call option, $180.00 strike price, at 11:13 AM with a limit buy. We exited 3 hours later by limit sale for a 100% profit!
Cleared final positions after Joe Biden Spoke.(More)
NVAX: NOVAVAX INC
Tuesday, December 21, 2021 20:12:17 UTC
NOVAVAX INC: We entered a call option, $180.00 strike price, at 11:13 AM with a limit buy. We exited 3 hours later by limit sale for a 100% profit!
Cleared final positions after Joe Biden Spoke.
#nvax #bntx #pfe #mrna #novavaxinc #nvax #novavaxinc #covid #vaccine #pfizer #who #biontech
Monday, December 20, 2021 12:57:10 UTC
With an emergency approval for use by the WHO, Novavax is ripping in premarket, and options have been historically adjusting very well for this stock.
The stock increased after World Health Organization granted the vaccine company and the Serum Institute of India an emergency use authorization for their Covid-19 vaccine.
Covovax, which is manufactured and marketed by the Serum Institute for India and other developing nations, has been awarded emergency use status by the WHO.
Novavax's Covid-19 vaccine is protein-based, unlike the vaccines developed by the Pfizer (PFE) and BioNTech (BNTX) alliance and Moderna (MRNA), which are based on messenger RNA drug technology.
NOTE: This is not an endorsement or rejection of vaccines. This is a stock market news item.(More)
NOVAVAX APPROVED FOR EMERGENCY USE
Monday, December 20, 2021 12:57:10 UTC
With an emergency approval for use by the WHO, Novavax is ripping in premarket, and options have been historically adjusting very well for this stock.
The stock increased after World Health Organization granted the vaccine company and the Serum Institute of India an emergency use authorization for their Covid-19 vaccine.
Covovax, which is manufactured and marketed by the Serum Institute for India and other developing nations, has been awarded emergency use status by the WHO.
Novavax's Covid-19 vaccine is protein-based, unlike the vaccines developed by the Pfizer (PFE) and BioNTech (BNTX) alliance and Moderna (MRNA), which are based on messenger RNA drug technology.
NOTE: This is not an endorsement or rejection of vaccines. This is a stock market news item.
PFIZER MAY HAVE OMICRON BEAT
12.8.21 1:03 PM UTC
Pfizer and BioNTech have announced a two-shot vaccine, plus a third booster was able to neutralize the new Omicron variant, and could be ready by March 2022.
PFIZER MAY HAVE OMICRON BEAT
Wednesday, December 08, 2021 13:03:58 UTC
Pfizer and BioNTech have announced a two-shot vaccine, plus a third booster was able to neutralize the new Omicron variant, and could be ready by March 2022.
#pfizer #biontech #omicron #covid #americanairlines #booster #vaccine
OMICRON CASES APPROACHING HALF OF USA
12.6.21 12:58 PM UTC
Cases of the latest Covid variant, omicron have been identified in a third of all U.S. states. The FDA looks to expedite authorization for modified vaccines.
OMICRON CASES APPROACHING HALF OF USA
Monday, December 06, 2021 12:58:13 UTC
Cases of the latest Covid variant, omicron have been identified in a third of all U.S. states. The FDA looks to expedite authorization for modified vaccines.
#covid #pfizer #pfe #biontech #bntc #moderna #mrna #vaccine #omicron